SP-600125 10mg | ≥98%
CSNpharm
SP-600125 is a competitive and reversible JNK inhibitor with IC50 values of 40 nM, 40 nM and 90 nM for JNK1, 2 and 3.
More Information Supplier PageSP-600125
Search Results
SP-600125 50mg | ≥98%
CSNpharm
SP-600125 is a competitive and reversible JNK inhibitor with IC50 values of 40 nM, 40 nM and 90 nM for JNK1, 2 and 3.
More Information Supplier PageSP-600125
Topotecan HCl 100mg | ≥99%
CSNpharm
Topotecan HCl is the first topoisomerase I-directed cytotoxic agent to enter clinical trials in the United States.
More Information Supplier PageTopotecan HCl
Topotecan HCl 10mg | ≥99%
CSNpharm
Topotecan HCl is the first topoisomerase I-directed cytotoxic agent to enter clinical trials in the United States.
More Information Supplier PageTopotecan HCl
ZM336372 50mg | ≥99%
CSNpharm
ZM336372
ZM336372 5mg | ≥99%
CSNpharm
ZM336372
ZM336372 10mg | ≥99%
CSNpharm
ZM336372
ZM241385 10mg | ≥99%
CSNpharm
ZM241385 is a high affinity antagonist ligand selective for the adenosine A2A receptor.
More Information Supplier PageZM241385
ZM241385 100mg | ≥99%
CSNpharm
ZM241385 is a high affinity antagonist ligand selective for the adenosine A2A receptor.
More Information Supplier PageZM241385
ZM241385 5mg | ≥99%
CSNpharm
ZM241385 is a high affinity antagonist ligand selective for the adenosine A2A receptor.
More Information Supplier PageZM241385